Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Nurse Treatment Preferences Survey for Intravenous Rituximab Infusion Versus Subcutaneous Rituximab Injection: A Real-World Study

Mitul D. Gandhi, MD, Sheila Shapouri, PharmD, MS, Arliene Ravelo, MPH, Lavanya Sudharshan, MS, Jamyia Clark, MPH, Keith L. Dawson, DNP, MS

Blood (2019) 134 (Supplement_1): 5890.

https://doi.org/10.1182/blood-2019-123739

Published: 2019

Journal Articles

A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life

Chaitra Ujjani, MD, Anthony R. Mato, MDMSCE, Jonathon B. Cohen, MDMS, Jakub Svoboda, MD, David Andorsky, MD, Andre Goy, MD, Michael L. Wang, MD, Anita Kumar, MD, Peggy Ann Torney, MS, Michelle Dawson, PhD, Cynthia Elesinmogun, PharmD, Shaum M Kabadi, PhDMPH, Brian Seal, MBA, PhD, John M. Pagel, MD PhD DSc, Scott D Ramsey, MD PhD

Blood (2019) 134 (Supplement_1): 5892.

https://doi.org/10.1182/blood-2019-122845

Published: 2019

Journal Articles

Patient-Reported Disease Burden and Age: Results from a National Patient Advocacy Survey of Patients with Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Keith L. Dawson, DNP, MS, Mark A. Price, MA, MD, Peggy Ann Torney, MS, Victor Gonzalez, MA, MS, Maria Sae-Hau, PhD, Elisa S. Weiss, PhD, Brennan Mange, BA, Carol Mansfield, PhD, Eydith J Comenencia-Ortiz, PhD, Anthony S Masaquel, PhD MPH, Arliene Ravelo, MPH

Blood (2019) 134 (Supplement_1): 4778.

https://doi.org/10.1182/blood-2019-123644

Published: 2019

Journal Articles

Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma

Tu My To, PhD, Keith L. Dawson, DNP, MS, Anthony S Masaquel, PhD MPH, Arpamas Seetasith, PhD

Blood (2019) 134 (Supplement_1): 4721.

https://doi.org/10.1182/blood-2019-123408

Published: 2019

Journal Articles

Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation

Giorgia Simonetti, PhD, Samantha Bruno, Carmine Onofrillo, PhD, Cristina Papayannidis, Giovanni Marconi, Michele Cavo, MD, Lorenzo Montanaro, MD PhD, Giovanni Martinelli

Blood (2018) 132 (Supplement 1): 2639.

https://doi.org/10.1182/blood-2018-99-117429

Published: 2018

Journal Articles

Long Term Outcome Following Splenectomy in Children

Tugberk Akca, MD, Zafer Salcioglu, Gonul Aydogan, MD, Tuba Nur Tahtakesen Güçer, MD, Cengiz Bayram, MD, Gul Nihal Ozdemir, MD

Blood (2018) 132 (Supplement 1): 5887.

https://doi.org/10.1182/blood-2018-99-116210

Published: 2018

Journal Articles

What Are Patients' Preferences and Satisfaction Regarding Modes of Administration for the Treatment of Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL)?

Mark Price, MA, MD, Arliene Ravelo, MPH, Elisa Weiss, PhD, Peggy Ann Torney, MS, Victor Gonzalez, MHC-LP, Maria Sae-Hau, PhD, Carol Mansfield, PhD, Eydith Comenencia-Ortiz, PhD, Miko Cunanan, BS, Anthony Masaquel, PhD MPH, Keith L Dawson, DNP

Blood (2018) 132 (Supplement 1): 5897.

https://doi.org/10.1182/blood-2018-99-115327

Published: 2018

Journal Articles

Synthetic Lethality of Combinatory Inhibition of BET and CDK7 in BET(i) Resistant Leukemia Cells

Lei Guo, PhD, Jia Li, PhD, Shaohai Fang, MS, Minjung Lee, MS, Hongxiang Zeng, PhD, Tingting Li, MD, Wei Han, MS, Deqiang Sun, PhD, Yun Huang, PhD

Blood (2018) 132 (Supplement 1): 1354.

https://doi.org/10.1182/blood-2018-99-116634

Published: 2018

Journal Articles

How Time Spent on Rituximab Infusion Impacts Patient Satisfaction, Stress, Employment, and Caregiver Burden

Maxine D Fisher, PhD, Christopher Wallick, PharmD, Paul J Miller, PhD, Mark S Walker, PhD, Stephen Lash, PharmD, Keith L Dawson, DNP, Carolina M Reyes, PhD

Blood (2017) 130 (Supplement 1): 5666.

https://doi.org/10.1182/blood.V130.Suppl_1.5666.5666

Published: 2017

Journal Articles

Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations

Giorgia Simonetti, PhD, Samantha Bruno, MSc, Carmine Onofrillo, PhD, Marco Malferrari, PhD, Cristina Papayannidis, MD PhD, Giovanni Marconi, MD, Michele Cavo, MD, Stefania Rapino, PhD, Lorenzo Montanaro, MD PhD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 3936.

https://doi.org/10.1182/blood.V130.Suppl_1.3936.3936

Published: 2017

Journal Articles

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Blood (2017) 130 (Supplement 1): 1377.

https://doi.org/10.1182/blood.V130.Suppl_1.1377.1377

Published: 2017

Journal Articles

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Neil L Berinstein, MD, Nancy M Pennell, BSc, Rashmi Weerasinghe, Matthew C. Cheung, MD SM, FRCPC, Eugenia Piliotis, MD FRCP, MD, Kevin R Imrie, MD, Mary-Anne Cussen, Rena Buckstein, MD, Zeina Ghorab, Ellen Miles, Marciano D. Reis, MD

Blood (2016) 128 (22): 1794.

https://doi.org/10.1182/blood.V128.22.1794.1794

Published: 2016

Journal Articles

Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

Xiu Ly Song, Raphaël Szalat, MD, Alexis Talbot, MD, HaiVu Nguyen, PhD, Mehmet K. Samur, PhD, David Mosen-Ansorena, PhD, Nikhil C. Munshi, MD, Stephane Minvielle, PhD, Herve Avet Loiseau, MD PhD, Wendy Cuccuini, MD PhD, Jean-Paul Fermand, MD, Bertrand Arnulf, MD PhD, Jean-Christophe Bories

Blood (2016) 128 (22): 4462.

https://doi.org/10.1182/blood.V128.22.4462.4462

Published: 2016

Journal Articles

Disease Characteristics, Treatment Patterns, and Outcomes of Follicular Lymphoma in Patients 40 Years of Age and Younger: An Analysis from the National LymphoCare Study

Carla Casulo, MD, Michelle Byrtek, PhD, Keith L Dawson, DNP, MS, Xiaolei Zhou, MS, Christopher R. Flowers, MD, Charles M. Farber, MD PhD, John D Hainsworth, MD, James R Cerhan, MD PhD, Brian K Link, MD, Jonathan W Friedberg, MD

Blood (2014) 124 (21): 3044.

https://doi.org/10.1182/blood.V124.21.3044.3044

Published: 2014

Journal Articles

Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients

Lenka Kubiczkova-Besse, Daniela Drandi, Lenka Sedlarikova, Stefania Oliva, MD, Manuela Gambella, Paola Omedè, PhD, Zdenek Adam, prof, MD PhD, Ludek Pour, Doc, MD PhD, Sabina Sevcikova, PhD, Mario Boccadoro, MD, Antonio Palumbo, MD, Roman Hajek, Prof, MD PhD

Blood (2014) 124 (21): 3423.

https://doi.org/10.1182/blood.V124.21.3423.3423

Published: 2014

Journal Articles

Fingolimod Expands Human Umbilical Cord Blood Cells (UCB) in Vitro and Improves Engraftment Rate of Human UCB in Sublethally Irradiated NOD SCID Gamma (NSG) Mice

Basem M. William, MD, Stephen Moreton, Jane Reese, Pingfu Fu, Ph., D., Julia V. Busik, PhD, Marcos de Lima, MD, David N. Wald, MD PhD

Blood (2014) 124 (21): 2413.

https://doi.org/10.1182/blood.V124.21.2413.2413

Published: 2014

Journal Articles

PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study

Ida Wong-Sefidan, MD, Michelle Byrtek, PhD, Xiaolei Zhou, MS, Jonathan W. Friedberg, MD, Christopher Flowers, MD, Brian K Link, MD, Andrew D. Zelenetz, MD, PhD, Keith L Dawson, DNP, RN, Erin G. Reid, MD, MS

Blood (2013) 122 (21): 4245.

https://doi.org/10.1182/blood.V122.21.4245.4245

Published: 2013

Journal Articles

A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients

Chadi Nabhan, MD, FACP, Michelle Byrtek, PhD, Keith L Dawson, DNP, RN, Xiaolei Zhou, MS, Brian K Link, MD, Jonathan W. Friedberg, MD, Andrew D. Zelenetz, MD, PhD, James R Cerhan, MD, PhD, Christopher R. Flowers, MD, MS

Blood (2013) 122 (21): 3058.

https://doi.org/10.1182/blood.V122.21.3058.3058

Published: 2013

Journal Articles

Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study

Carla Casulo, MD, Michelle Byrtek, PhD, Keith L. Dawson, DNP, RN, Xiaolei Zhou, MS, Charles Farber, MD, Christopher R. Flowers, MD, MS, John D. Hainsworth, MD, Brian K Link, MD, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 510.

https://doi.org/10.1182/blood.V122.21.510.510

Published: 2013

Journal Articles

Outcome of SSPE

Blood (2013) 122 (7): 1329.

https://doi.org/10.1182/blood-2013-07-515965

Published: 2013

NARROW

Nurse Treatment Preferences Survey for Intravenous Rituximab Infusion Versus Subcutaneous Rituximab Injection: A Real-World Study

A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life

Patient-Reported Disease Burden and Age: Results from a National Patient Advocacy Survey of Patients with Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma

Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation

Long Term Outcome Following Splenectomy in Children

What Are Patients' Preferences and Satisfaction Regarding Modes of Administration for the Treatment of Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL)?

Synthetic Lethality of Combinatory Inhibition of BET and CDK7 in BET(i) Resistant Leukemia Cells

How Time Spent on Rituximab Infusion Impacts Patient Satisfaction, Stress, Employment, and Caregiver Burden

Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

Disease Characteristics, Treatment Patterns, and Outcomes of Follicular Lymphoma in Patients 40 Years of Age and Younger: An Analysis from the National LymphoCare Study

Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients

Fingolimod Expands Human Umbilical Cord Blood Cells (UCB) in Vitro and Improves Engraftment Rate of Human UCB in Sublethally Irradiated NOD SCID Gamma (NSG) Mice

PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study

A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients

Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study

Outcome of SSPE

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only